Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14WZY | ISIN: US9034801012 | Ticker-Symbol: UNC0
Siehe auch UCB SA
Frankfurt
27.06.25 | 08:02
84,50 Euro
+1,20 % +1,00
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
UCB SA ADR Chart 1 Jahr
5-Tage-Chart
UCB SA ADR 5-Tage-Chart

Aktuelle News zur UCB SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrUCB plots regulatory filings as Fintepla shows potential to treat a 3rd epilepsy disorder1
FrUCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder120Phase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine...
► Artikel lesen
UCB SA ADR Aktie jetzt für 0€ handeln
DiTD Cowen reiterates buy rating on UCB stock amid Bimzelx optimism2
MoUCB jumps over 4% after Morgan Stanley upgrades to "overweight"5
MoMorgan Stanley stuft UCB-Aktie aufgrund der Bimzelx-Verkaufsaussichten hoch15
MoMorgan Stanley upgrades UCB stock rating on Bimzelx sales outlook3
20.06.UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference171UCB will contribute three presentations, including data on the disease course of thymidine kinase 2 deficiency (TK2d) in untreated patients and insights into caregiver...
► Artikel lesen
13.06.Data at EULAR back Biogen, UCB's first-in-class lupus drug7
13.06.UCB To Invest In U.S. Biologics Facility With $5 Bln Economic Impact5
12.06.UCB touts plan for 'major' US investment to boost biologics capacity3
12.06.Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results9
12.06.UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal350WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L...
► Artikel lesen
12.06.UCB: BIMZELX 3-Year Results Confirm Sustained Efficacy In Psoriatic And Axial Spondyloarthritis2
11.06.UCB: BIMZELX (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis159Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients...
► Artikel lesen
11.06.UCB's Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials3
20.05.Raymond James lifts UCB stock price target to $3219
30.04.J&J joins Argenx, UCB in the myasthenia gravis arena with FDA approval for FcRn blocker Imaavy20
24.04.UCB partners with Dr. Pimple Popper in ongoing hidradenitis suppurativa campaign6
25.03.TD Cowen maintains UCB stock Buy rating, EUR250 target39
21.03.UCB Convening Notice to the General Meeting of the Shareholders 2025738CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the "General Meeting") which will be...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1